Alto Neuroscience
https://www.altoneuroscience.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Alto Neuroscience
Scrip Asks…What Does 2022 Hold For Biopharma? Part 5: Clinical Trials
The COVID-19 pandemic drove huge shifts in clinical trial practice and the transformation is expected to continue even after the global health emergency abates. Industry leaders sharing their predictions around clinical development homed in on decentralized trials, digitization and data tools as key topics for 2022.
Finance Watch: 2021 Biopharma VC Funding Tops Full-Year 2020 Total
Private Company Edition: The industry raised $28bn in venture capital through the third quarter, breaking the record $27.4bn raised last year. Also, big pharmas backed a start-up lab in Israel, plus mega-rounds for CinCor Pharma ($143m) and Rectify Pharmaceuticals ($100m), while Cerecin raises $40m.
Cerecor Turns The LIGHT Back On As Avalo, With PRV Haul In Sight
The former Cerecor boasts four pipeline assets that could yield US FDA priority review vouchers. Having divested CNS assets, the renamed firm will focus on IBD with first-in-class anti-LIGHT candidate, plus immunology and rare diseases.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Medical Devices
- Diagnostic Equipment & Supplies
-
Digital Health
- Artificial Intelligence